PURPOSE: The results of bladder sparing approach for the treatment of muscle- @entity150 , using a combination of transurethral resection (TUR), chemotherapy, and radiotherapy, are encouraging. The survival of @entity1 treated by this method is similar to the survival of @entity1 treated by radical cystectomy. The aim of our study was to find out which pretreatment characteristics influence the survival of @entity1 treated by organ sparing approach that would enable us to identify the @entity1 most suitable for this type of treatment. METHODS AND MATERIALS: The prognostic value of different factors, such as age, gender, performance status, hemoglobin level, clinical stage, histologic grade, presence of @entity3551 , and completeness of TUR, has been studied in 105 @entity1 with @entity150 , who received a bladder sparing treatment in the period from 1988 to 1995. They were treated with a combination of TUR, followed by 2-4 cycles of @entity1499 , @entity900 , and @entity5713 polychemotherapy. In complete responders the treatment was completed by radiotherapy (50 Gy to the bladder and 40 Gy to the regional lymph nodes), whereas nonresponders underwent cystectomy whenever feasible. RESULTS: Our study has confirmed an independent prognostic value of performance status, histologic grade, @entity3551 , for the disease-specific survival (DSS) of @entity150 @entity1 treated by a conservative approach. We believe that performance status best reflects the extent of disease and exerts significant influence on the extent and course of treatment, @entity3551 is a good indicator of local spread of the disease, better than clinical T-stage. Our finding that histologic grade is one of the strongest prognostic factors shows that @entity5 biology also is a very important prognostic factor in @entity1 treated by conservative approach. CONCLUSION: @entity1 with muscle- @entity150 who are most likely to benefit from conservative treatment approach include those with good performance status, absence of @entity3041 , and histologic low grade transitional cell @entity189 .

Prognostic factors in invasive XXXX treated by combined modality protocol (organ-sparing approach).

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity3551 :: ('MESH:C536483', 'Disease') :: ['and obstructive uropathy', 'while obstructive uropathy', 'obstructive uropathy'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatinum'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma'] @entity3041 :: ('MESH:D006869', 'Disease') :: ['hydronephrosis'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer', 'invasive bladder cancer'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']
@entity150 :: (MESH:D001749,Disease) :: ['bladder carcinoma']
